Published Erratum
doi: 10.1016/j.apsb.2022.04.004.
Epub 2022 Apr 8.
Erratum: Author correction to 'Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling' [Acta Pharmaceutica Sinica B 12 (2022) 1198-1212]
Affiliations
- PMID: 35865100
- PMCID: PMC9293698
- DOI: 10.1016/j.apsb.2022.04.004
Item in Clipboard
Published Erratum
Erratum: Author correction to 'Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling' [Acta Pharmaceutica Sinica B 12 (2022) 1198-1212]
Acta Pharm Sin B.
2022 Jul.
Abstract
[This corrects the article DOI: 10.1016/j.apsb.2021.09.017.].
© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Erratum for
-
Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling.Acta Pharm Sin B. 2022 Mar;12(3):1198-1212. doi: 10.1016/j.apsb.2021.09.017. Epub 2021 Sep 22. Acta Pharm Sin B. 2022. PMID: 35530141 Free PMC article.
Similar articles
-
Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling.Acta Pharm Sin B. 2022 Mar;12(3):1198-1212. doi: 10.1016/j.apsb.2021.09.017. Epub 2021 Sep 22. Acta Pharm Sin B. 2022. PMID: 35530141 Free PMC article.
-
Erratum: Author correction to 'Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome' [Acta Pharmaceutica Sinica B 9 (2019) 734-744].Acta Pharm Sin B. 2020 Dec;10(12):2433-2434. doi: 10.1016/j.apsb.2020.09.011. Epub 2020 Sep 24. Acta Pharm Sin B. 2020. PMID: 33354512 Free PMC article.
-
Erratum: Author correction to "A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer's disease" [Acta Pharmaceutica Sinica B 12, (2021) 4032-4044].Acta Pharm Sin B. 2022 Jun;12(6):2965-2967. doi: 10.1016/j.apsb.2022.04.008. Epub 2022 Apr 15. Acta Pharm Sin B. 2022. PMID: 35755290 Free PMC article.
-
Erratum: Author correction to 'Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice' [Acta Pharmaceutica Sinica B 13 (2023) 1164-1179].Acta Pharm Sin B. 2023 Aug;13(8):3575-3576. doi: 10.1016/j.apsb.2023.07.003. Epub 2023 Jul 6. Acta Pharm Sin B. 2023. PMID: 37655316 Free PMC article.
-
Erratum: Author correction to "YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer" [Acta Pharmaceutica Sinica B 12 (2022) 2845-2858].Acta Pharm Sin B. 2023 Jul;13(7):3178-3179. doi: 10.1016/j.apsb.2023.05.003. Epub 2023 May 9. Acta Pharm Sin B. 2023. PMID: 37521865 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
